GATA zinc finger domain-containing protein 2B (GATAD2B)

GATA zinc finger domain-containing protein 2B (GATAD2B) is a transcriptional repressor and a core component of the NuRD (nucleosome remodeling and deacetylase) complex, a multi-protein assembly that regulates gene expression by remodeling chromatin structure and deacetylating histones[1][2][3]. GATAD2B contains two conserved domains (CR1 and CR2) essential for bridging the methyl-CpG-binding domain (MBD) proteins and chromatin-helicase DNA-binding (CHD) proteins, positioning it as a molecular “bridge” within the NuRD complex[1]. It plays a critical role in neurodevelopment, and pathogenic variants—particularly loss-of-function or dominant-negative missense mutations—can disrupt NuRD assembly and lead to GATAD2B-associated neurodevelopmental disorder (GAND), characterized by intellectual disability, motor and speech impairments, and congenital anomalies, especially affecting the heart and nervous system[1][3]. There are no known therapeutic drugs or direct pharmacological modulators currently targeting GATAD2B; its primary biomedical relevance is in disease genetics and functional chromatin biology[2][3].

Other names

Transcriptional repressor p66-betaKIAA1150P66betap66/p68transcription repressor p66 beta component of the MeCP1 complexGANDSMRD18p68